{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T01:46:19Z","timestamp":1776217579712,"version":"3.50.1"},"reference-count":46,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2021,11,29]],"date-time":"2021-11-29T00:00:00Z","timestamp":1638144000000},"content-version":"vor","delay-in-days":455,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Adjuvant chemotherapy with 5-fluorouracil (5-FU) and oxaliplatin increases recurrence-free and overall survival in patients with colon adenocarcinoma. It is known that these drugs have been associated with cardio- and neurotoxicity. We investigated the effects of 5-FU \u00b1 oxaliplatin on cardiac function, vascular responses, neurovascular control, and physical capacity in patients with colon cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Twenty-nine patients with prior colectomy for stage II\u2013III adenocarcinoma and clinical indication for adjuvant chemotherapy were allocated to receive 5-FU (n =\u200912) or 5-FU + oxaliplatin (n =\u200917), according to the oncologist's decision. All the analyses were performed just before and after the end of chemotherapy. Cardiac function was assessed by echocardiography and speckle tracking, and cardiac autonomic control was assessed by heart rate variability (HRV). Vascular endothelial function was assessed by flow-mediated dilation (FMD). Muscle sympathetic nerve activity (MSNA) was directly recorded by microneurography technique, and muscle blood flow by venous occlusion plethysmography. Physical capacity was evaluated by cardiopulmonary exercise test.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Chemotherapy (pooled data) did not significantly change left ventricular ejection fraction (58 \u00b1\u20091 vs. 55 \u00b1\u20092%, p = .14), longitudinal strain (\u221218 \u00b1\u20091 vs. \u221218 \u00b1\u20091%, p = .66), and HRV. Likewise, chemotherapy did not significantly change FMD, muscle blood flow, and MSNA (33 \u00b1\u20092 vs. 32 \u00b1\u20091 bursts\/min, p = .31). Physical capacity was not significantly changed in both groups. Similar findings were observed when the patients were subdivided in 5-FU and 5-FU + oxaliplatin treatment groups. 5-FU and 5-FU + oxaliplatin did not significantly change cardiac function, HRV, vascular responses, MSNA, and physical capacity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study provides evidence that adjuvant treatment with 5-FU \u00b1 oxaliplatin is well tolerated and does not promote changes compatible with long-term cardiotoxicity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Implications for Practice<\/jats:title>\n                    <jats:p>Adjuvant chemotherapy with 5-fluorouracil (5-FU) and oxaliplatin increases recurrence-free and overall survival in patients with colon adenocarcinoma; however, these drugs have been associated with cardio- and neurotoxicity. This study investigated the effects of these drugs on cardiac function, vascular responses, neurovascular control, and physical capacity in patients with colon cancer. It was found that 5-FU and oxaliplatin did not significantly change cardiac function, cardiac autonomic control, vascular endothelial function, muscle sympathetic nerve activity, and physical capacity. This study provides evidence that adjuvant treatment with 5-FU \u00b1 oxaliplatin is well tolerated and does not promote changes compatible with long-term cardiotoxicity.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1634\/theoncologist.2020-0225","type":"journal-article","created":{"date-parts":[[2020,8,6]],"date-time":"2020-08-06T21:26:24Z","timestamp":1596749184000},"page":"e1956-e1967","source":"Crossref","is-referenced-by-count":11,"title":["Adjuvant Treatment with 5-Fluorouracil and Oxaliplatin Does Not Influence Cardiac Function, Neurovascular Control, and Physical Capacity in Patients with Colon Cancer"],"prefix":"10.1093","volume":"25","author":[{"given":"Raphaela V.","family":"Groehs","sequence":"first","affiliation":[{"name":"Instituto do Coracao (InCor), Universidade de S\u00e3o Paulo , S\u00e3o Paulo,","place":["Brasil"]},{"name":"Hospital Israelita Albert Einstein , S\u00e3o Paulo,","place":["Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcelo V.","family":"Negrao","sequence":"additional","affiliation":[{"name":"Department of Thoracic\/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center , Houston, Texas,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ludhmila A.","family":"Hajjar","sequence":"additional","affiliation":[{"name":"Instituto do Coracao (InCor), Universidade de S\u00e3o Paulo , S\u00e3o Paulo,","place":["Brasil"]},{"name":"Instituto do Cancer do Estado de Sao Paulo, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de S\u00e3o Paulo , S\u00e3o Paulo,","place":["Brasil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camila P.","family":"Jord\u00e3o","sequence":"additional","affiliation":[{"name":"Instituto do Coracao (InCor), Universidade de S\u00e3o Paulo , S\u00e3o Paulo,","place":["Brasil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruna P.","family":"Carvalho","sequence":"additional","affiliation":[{"name":"Instituto do Coracao (InCor), Universidade de S\u00e3o Paulo , S\u00e3o Paulo,","place":["Brasil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edgar","family":"Toschi-Dias","sequence":"additional","affiliation":[{"name":"Instituto do Coracao (InCor), Universidade de S\u00e3o Paulo , S\u00e3o Paulo,","place":["Brasil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana C.","family":"Andrade","sequence":"additional","affiliation":[{"name":"Instituto do Coracao (InCor), Universidade de S\u00e3o Paulo , S\u00e3o Paulo,","place":["Brasil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabiana P.","family":"Hodas","sequence":"additional","affiliation":[{"name":"Instituto do Coracao (InCor), Universidade de S\u00e3o Paulo , S\u00e3o Paulo,","place":["Brasil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria J.N.N.","family":"Alves","sequence":"additional","affiliation":[{"name":"Instituto do Coracao (InCor), Universidade de S\u00e3o Paulo , S\u00e3o Paulo,","place":["Brasil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adriana O.","family":"Sarmento","sequence":"additional","affiliation":[{"name":"Instituto do Coracao (InCor), Universidade de S\u00e3o Paulo , S\u00e3o Paulo,","place":["Brasil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Testa","sequence":"additional","affiliation":[{"name":"Instituto do Cancer do Estado de Sao Paulo, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de S\u00e3o Paulo , S\u00e3o Paulo,","place":["Brasil"]},{"name":"D'Or Institute for Research and Education (IDOR) , S\u00e3o Paulo,","place":["Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paulo M.G.","family":"Hoff","sequence":"additional","affiliation":[{"name":"Instituto do Cancer do Estado de Sao Paulo, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de S\u00e3o Paulo , S\u00e3o Paulo,","place":["Brasil"]},{"name":"D'Or Institute for Research and Education (IDOR) , S\u00e3o Paulo,","place":["Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos E.","family":"Negrao","sequence":"additional","affiliation":[{"name":"Instituto do Coracao (InCor), Universidade de S\u00e3o Paulo , S\u00e3o Paulo,","place":["Brasil"]},{"name":"Escola de Educa\u00e7\u00e3ao F\u00edsica e Esporte, Universidade de S\u00e3o Paulo , S\u00e3o Paulo,","place":["Brasil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto Kalil","family":"Filho","sequence":"additional","affiliation":[{"name":"Instituto do Coracao (InCor), Universidade de S\u00e3o Paulo , S\u00e3o Paulo,","place":["Brasil"]},{"name":"S\u00edrio-Liban\u00eas Hospital , S\u00e3o Paulo,","place":["Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,8,31]]},"reference":[{"key":"2026041420243361300_onco13475-cit-0001","first-page":"177","article-title":"Colorectal cancer statistics, 2017","volume":"67","author":"Siegel","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"2026041420243361300_onco13475-cit-0002","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1038\/521S1a","article-title":"Colorectal cancer","volume":"521","author":"Brody","year":"2015","journal-title":"Nature"},{"key":"2026041420243361300_onco13475-cit-0003","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"2026041420243361300_onco13475-cit-0004","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1200\/JCO.2008.20.6771","article-title":"Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial","volume":"27","author":"Andr\u00e9","year":"2009","journal-title":"J Clin Oncol"},{"key":"2026041420243361300_onco13475-cit-0005","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1200\/JCO.1997.15.2.808","article-title":"Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: A French intergroup study","volume":"15","author":"Gramont","year":"1997","journal-title":"J Clin Oncol"},{"key":"2026041420243361300_onco13475-cit-0006","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1016\/S0140-6736(07)61866-2","article-title":"Adjuvant chemotherapy versus observation in patients with colorectal cancer: A randomised study","volume":"370","author":"QUASAR Collaborative Group","year":"2007","journal-title":"Lancet"},{"key":"2026041420243361300_onco13475-cit-0007","doi-asserted-by":"crossref","first-page":"3732","DOI":"10.1200\/JCO.2007.12.2234","article-title":"Phase III study comparing a semimonthly with a monthly regimen of fluorouracil and leucovorin as adjuvant treatment for stage II and III colon cancer patients: Final results of GERCOR C96","volume":"25","author":"Andr\u00e9","year":"2007","journal-title":"1. J Clin Oncol"},{"key":"2026041420243361300_onco13475-cit-0008","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1056\/NEJMoa032709","article-title":"Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer","volume":"350","author":"Andre","year":"2004","journal-title":"N Engl J Med"},{"key":"2026041420243361300_onco13475-cit-0009","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1200\/JCO.2006.08.2974","article-title":"Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: Results from NSABP C-07","volume":"25","author":"Kuebler","year":"2007","journal-title":"J Clin Oncol"},{"key":"2026041420243361300_onco13475-cit-0010","doi-asserted-by":"crossref","first-page":"4176","DOI":"10.1200\/JCO.2015.63.4238","article-title":"Adjuvant fluorouracil, leucovorin, and oxaliplatin in stage II to III colon cancer: Updated 10-year survival and outcomes according to BRAF mutation and mismatch repair status of the MOSAIC study","volume":"33","author":"Andr\u00e9","year":"2015","journal-title":"J Clin Oncol"},{"key":"2026041420243361300_onco13475-cit-0011","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1177\/106002809402800314","article-title":"Fluorouracil cardiotoxicity","volume":"28","author":"Anand","year":"1994","journal-title":"Ann Pharmacother"},{"key":"2026041420243361300_onco13475-cit-0012","doi-asserted-by":"crossref","DOI":"10.1177\/1758835918780140","article-title":"5-fluorouracil and cardiotoxicity: A review","volume":"10","author":"Sara","year":"2018","journal-title":"Ther Adv Med Oncol"},{"key":"2026041420243361300_onco13475-cit-0013","doi-asserted-by":"crossref","first-page":"453","DOI":"10.5603\/CJ.2012.0084","article-title":"5-fluorouracil induced cardiotoxicity: Review of the literature","volume":"19","author":"Sorrentino","year":"2012","journal-title":"Cardiol J"},{"key":"2026041420243361300_onco13475-cit-0014","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1177\/030089168206800609","article-title":"Cardiac toxicity of 5-fluorouracil: A study on 1083 patients","volume":"68","author":"Labianca","year":"1982","journal-title":"Tumori"},{"key":"2026041420243361300_onco13475-cit-0015","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1093\/annonc\/mdu055","article-title":"Effort myocardial ischemia during chemotherapy with 5-fluorouracil: An underestimated risk","volume":"25","author":"Lestuzzi","year":"2014","journal-title":"Ann Oncol"},{"key":"2026041420243361300_onco13475-cit-0016","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/0167-8140(88)90296-4","article-title":"Adverse cardiac effects during induction chemotherapy treatment with cis-platin and 5-fluorouracil","volume":"13","author":"Eskilsson","year":"1988","journal-title":"Radiother Oncol"},{"key":"2026041420243361300_onco13475-cit-0017","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1093\/jjco\/hyh047","article-title":"Evaluation of cardiotoxicity of a combined bolus plus infusional 5-fluorouracil\/folinic acid treatment by echocardiography, plasma troponin I level, QT interval and dispersion in patients with gastrointestinal system cancers","volume":"34","author":"Oztop","year":"2004","journal-title":"Jpn J Clin Oncol"},{"key":"2026041420243361300_onco13475-cit-0018","doi-asserted-by":"crossref","first-page":"169","DOI":"10.4103\/0973-1482.37412","article-title":"Transient asymptomatic bradycardia in patients on infusional 5-fluorouracil","volume":"3","author":"Talapatra","year":"2007","journal-title":"J Cancer Res Ther"},{"key":"2026041420243361300_onco13475-cit-0019","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/j.1875-9114.1997.tb03748.x","article-title":"Symptomatic cardiotoxicity associated with 5-fluorouracil","volume":"17","author":"Meyer","year":"1997","journal-title":"Pharmacotherapy"},{"key":"2026041420243361300_onco13475-cit-0020","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1002\/1097-0142(19931001)72:7<2242::AID-CNCR2820720730>3.0.CO;2-E","article-title":"Cardiotoxicity of 5-fluorouracil in combination with folinic acid in patients with gastrointestinal cancer","volume":"72","author":"Schober","year":"1993","journal-title":"Cancer"},{"key":"2026041420243361300_onco13475-cit-0021","first-page":"93","article-title":"Literature review and practical aspects on the management of oxaliplatin-associated toxicity","volume":"11","author":"Hoff","year":"2012","journal-title":"Clin Colorectal Cancer"},{"key":"2026041420243361300_onco13475-cit-0022","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/ajco.12694","article-title":"Factors associated with the development and severity of oxaliplatin-induced peripheral neuropathy: A systematic review","volume":"13","author":"Pulvers","year":"2017","journal-title":"Asia Pac J Clin Oncol"},{"key":"2026041420243361300_onco13475-cit-0023","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.neulet.2014.10.014","article-title":"Chemotherapy-induced peripheral neuropathy: What do we know about mechanisms?","volume":"596","author":"Carozzi","year":"2015","journal-title":"Neurosci Lett"},{"key":"2026041420243361300_onco13475-cit-0024","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1111\/ene.12514","article-title":"The impact of oxaliplatin-based chemotherapy for colorectal cancer on the autonomous nervous system","volume":"21","author":"Dermitzakis","year":"2014","journal-title":"Eur J Neurol"},{"key":"2026041420243361300_onco13475-cit-0025","first-page":"1409","article-title":"Adverse effects on cardiovascular status and lipid levels of albino Wistar rats treated with cisplatin and oxaliplatin in combination with 5 fluorouracil","volume":"27","author":"Najam","year":"2014","journal-title":"Pak J Pharm Sci"},{"key":"2026041420243361300_onco13475-cit-0026","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3892\/mco.2012.12","article-title":"Modified FLOX as first-line chemotherapy for metastatic colorectal cancer patients in the public health system in Brazil: Effectiveness and cost-utility analysis","volume":"1","author":"Nebuloni","year":"2013","journal-title":"Mol Clin Oncol"},{"key":"2026041420243361300_onco13475-cit-0027","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/S0735-1097(03)00831-3","article-title":"The effects of exercise training on sympathetic neural activation in advanced heart failure","volume":"42","author":"Roveda","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"2026041420243361300_onco13475-cit-0028","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.echo.2014.10.003","article-title":"Recommendations for cardiac chamber quantification by echocardiography in adults: An update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"28","author":"Lang","year":"2015","journal-title":"J Am Soc Echocardiogr"},{"key":"2026041420243361300_onco13475-cit-0029","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1016\/j.jacc.2014.01.073","article-title":"Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: A systematic review","volume":"63","author":"Thavendiranathan","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2026041420243361300_onco13475-cit-0030","doi-asserted-by":"crossref","first-page":"H2","DOI":"10.1152\/ajpheart.00471.2010","article-title":"Assessment of flow-mediated dilation in humans: A methodological and physiological guideline","volume":"300","author":"Thijssen","year":"2011","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2026041420243361300_onco13475-cit-0031","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/HJH.0b013e32835b8164","article-title":"A new approach to improve the specificity of flow-mediated dilation for indicating endothelial function in cardiovascular research","volume":"31","author":"Atkinson","year":"2013","journal-title":"J Hypertens"},{"key":"2026041420243361300_onco13475-cit-0032","first-page":"65","volume-title":"Cardiovascular Reflex Control in Health and Disease","author":"Wallin","year":"1993"},{"key":"2026041420243361300_onco13475-cit-0033","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1161\/01.CIR.0000047275.25795.17","article-title":"Short-term heart rate variability strongly predicts sudden cardiac death in chronic heart failure patients","volume":"107","author":"La Rovere","year":"2003","journal-title":"Circulation"},{"key":"2026041420243361300_onco13475-cit-0034","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1093\/oxfordjournals.eurheartj.a014868","article-title":"Heart rate variability. Standards of measurement, physiological interpretation, and clinical use","volume":"17","author":"Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology","year":"1996","journal-title":"Eur Heart J"},{"key":"2026041420243361300_onco13475-cit-0035","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1093\/eurjhf\/hfp168","article-title":"Impact of gender on benefits of exercise training on sympathetic nerve activity and muscle blood flow in heart failure","volume":"12","author":"Antunes-Correa","year":"2010","journal-title":"Eur J Heart Fail"},{"key":"2026041420243361300_onco13475-cit-0036","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1177\/2047487316654025","article-title":"Muscle electrical stimulation improves neurovascular control and exercise tolerance in hospitalised advanced heart failure patients","volume":"23","author":"Groehs","year":"2016","journal-title":"Eur J Prev Cardiol"},{"key":"2026041420243361300_onco13475-cit-0037","first-page":"887","article-title":"Left ventricular function in colon cancer patients receiving adjuvant fluoro-folate chemotherapy: An echocardiographic study","volume":"7","author":"Balloni","year":"2000","journal-title":"Oncol Rep"},{"key":"2026041420243361300_onco13475-cit-0038","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s00280-011-1669-x","article-title":"5-Fluorouracil-based therapy induces endovascular injury having potential significance to development of clinically overt cardiotoxicity","volume":"69","author":"Jensen","year":"2012","journal-title":"Cancer Chemother Pharmacol"},{"key":"2026041420243361300_onco13475-cit-0039","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1023\/A:1008263321681","article-title":"Noninvasive evaluation of cardiotoxicity of 5-fluorouracil and low doses of folinic acid: A one-year follow-up study","volume":"8","author":"Grandi","year":"1997","journal-title":"Ann Oncol"},{"key":"2026041420243361300_onco13475-cit-0040","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.ijcard.2008.03.056","article-title":"Increased muscle sympathetic nerve activity predicts mortality in heart failure patients","volume":"135","author":"Barretto","year":"2009","journal-title":"Int J Cardiol"},{"key":"2026041420243361300_onco13475-cit-0041","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1007\/s12032-009-9226-8","article-title":"5-fluorouracil induces arterial vasoconstrictions but does not increase angiotensin II levels","volume":"27","author":"Salepci","year":"2010","journal-title":"Med Oncol"},{"key":"2026041420243361300_onco13475-cit-0042","doi-asserted-by":"crossref","first-page":"H1","DOI":"10.1152\/ajpheart.00756.2018","article-title":"Chemotherapy acutely impairs neurovascular and hemodynamic responses in women with breast cancer","volume":"317","author":"Sales","year":"2019","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2026041420243361300_onco13475-cit-0043","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1002\/bjs.10112","article-title":"Validation of preoperative cardiopulmonary exercise testing-derived variables to predict in-hospital morbidity after major colorectal surgery","volume":"103","author":"West","year":"2016","journal-title":"Br J Surg"},{"key":"2026041420243361300_onco13475-cit-0044","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1308\/rcsann.2016.0135","article-title":"The impact of neoadjuvant chemotherapy on cardiopulmonary physical fitness in gastro-oesophageal adenocarcinoma","volume":"98","author":"Sinclair","year":"2016","journal-title":"Ann R Coll Surg Engl"},{"key":"2026041420243361300_onco13475-cit-0045","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1517\/14740330902733961","article-title":"Fluoropyrimidine-associated cardiotoxicity: Revisited","volume":"8","author":"Saif","year":"2009","journal-title":"Expert Opin Drug Saf"},{"key":"2026041420243361300_onco13475-cit-0046","doi-asserted-by":"crossref","first-page":"5280","DOI":"10.1200\/JCO.2009.27.3953","article-title":"Fluorouracil induces myocardial ischemia with increases of plasma brain natriuretic peptide and lactic acid but without dysfunction of left ventricle","volume":"28","author":"Jensen","year":"2010","journal-title":"J Clin Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1634%2Ftheoncologist.2020-0225","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2020-0225","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2020-0225","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/25\/12\/e1956\/41921569\/oncolo_25_12_n_a10.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/25\/12\/e1956\/41921569\/oncolo_25_12_n_a10.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:48:20Z","timestamp":1776214100000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/25\/12\/e1956\/6443944"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,31]]},"references-count":46,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2020-0225","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,12,1]]},"published":{"date-parts":[[2020,8,31]]}}}